stockrowGrifols, S.A.
GRFSHealthcare Drug Manufacturers General
Grifols, S.A.’s revenue for fiscal 2025 (year ended December 2025) was $8.5 billion, up 9.07% from fiscal 2024.
- Revenue
- +9.37%
- EPS
- +59.8%
- Free cash flow
- +4.11%
- Total debt
- −6.08%
Quarter to September 2026, against a year earlier
Follow GRFS
Alert me
Grifols, S.A. (GRFS) EV/Sales
As of 6 November 2026, Grifols, S.A. (GRFS) trades at a EV/Sales of 1.8×. Over the past ten years it has ranged from 1.3× (June 2024) to 4.9× (January 2018); the current reading is higher than 14% of that period. That is below the Drug Manufacturers General industry median of 4.1× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.9× | (8.86%) |
| FY2024 | 2.1× | 57.37% |
| FY2023 | 1.3× | (19.76%) |
| FY2022 | 1.7× | (4.14%) |
| FY2022 | 1.7× | 0.82% |
| FY2021 | 1.7× | (48.85%) |
| FY2021 | 3.4× | 1.71% |
| FY2020 | 3.3× | (15.30%) |
| FY2020 | 3.9× | 1.01% |
| FY2019 | 3.9× | 0.19% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 1.7× | (8.90%) |
| Mar 2026 | 1.8× | (3.76%) |
| Dec 2025 | 1.9× | (9.03%) |
| Sep 2025 | 2.1× | 3.17% |
| 29 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AMRN Amarin Corporation PLC compare | −0.4× |
| NSRX Nasus Pharma Ltd. compare | n/m |
| OGN Organon & Co. compare | 1.8× |
| GRFS Grifols, S.A. | 1.8× |
| SNY Sanofi compare | 2.1× |
| GSK GSK PLC Sponsored ADR compare | 2.9× |
| BMY Bristol Myers Squibb Company compare | 3.1× |
| NVO Novo Nordisk A/S compare | 3.7× |
| BIIB Biogen Inc. compare | 4.1× |
| Drug Manufacturers General industry median | 4.1× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on GRFS
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement